Speak with a Defective Drug Specialist
Get answers to legal & medical questions
patient advocate

 

Latest News

Date posted: 3/13/2013

As NuvaRing lawsuits over blood clots gear up to begin in state and federal courts, DrugRisk has learned that evidence filed by lawyers shows the maker of the devices may have known about elevated hormone risks, but concealed the results from the FDA and patients.

Although NuvaRing birth control devices have been on the market since 2001, women using the monthly plastic rings weren’t alerted of the risk of blood clots until recently, when independent researchers, not the maker of the device, started raising concerns.

In 2012, the New England Journal of Medicine, FDA and British Medical Journal all published findings that vaginal ring contraceptives like NuvaRing could have much higher risks for blood clots than traditional birth control pills.

Some studies related them to a 2.5 to 3-fold increased risk.

One explanation researchers developed was that, despite claims by the manufacturer that NuvaRing emitted lower doses of hormones, the constant and direct absorption of those hormones into the bloodstream could result in spiked hormone levels for some.

Elevated hormone levels have been linked to higher potassium levels in the bloodstream, which in turn can cause blood clots, stroke, DVT and pulmonary embolism.

According to the latest reports from the FDA, over 5,300 AERS adverse event reports have been filed for those using NuvaRings. Most common among the side effects are more than 2,300 cases of pulmonary embolism or thrombosis or deep vein thrombosis. In more than 30% of situations, victims required hospitalization.

Almost 1,100 women have already filed a NuvaRing lawsuit over allegations they suffered dangerous blood clots while using NuvaRing. Many of the cases have been moved to a special federal court in Missouri, while others are still in state courts.

Recently, lawyers representing a victim filed a study by Dr. Shelley Ann Tischkau, Ph.D. as court evidence, which states that the maker of NuvaRing, Organon (a subsidiary of Merck) may have concealed the risk of estrogen bursts in test patients to the FDA, which could contribute to the blood clot risks.*

If you or a family member suffered a blood clot, DVT, pulmonary embolism or stroke after using NuvaRing, it is recommended that you speak with a lawyer about your legal rights as soon as possible. Trials are set to start this year and time to file a new claim is limited.

Due to the specialized nature of defective drug injury cases, DrugRisk only recommends lawyers and law firms who have already handled NuvaRing lawsuits.

Contact us today for more information on the research, side effects and litigation news related to NuvaRing, or to speak with a lawyer.

*harrismartin.com/article/15848/mdl-judge-allows-expert-testimony-on-alleged-bursts-in-nuvarings-estrogen-delivery/